CXCL1 and experimental autoimmune encephalomyelitis: Overexpression and administration of recombinant CXCL1/KC suppresses murine autoimmune diseases such as experimental autoimmune encephalomyelitis (51) and autoimmune myocarditis; in the latter case treatment also reduced the numbers of autoreactive effector T cells specific to cardiac self-peptides (50).